Asset Details
Do you wish to reserve the book?
Antithymocyte globulin treatment at the time of transplantation impairs donor hematopoietic stem cell engraftment
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Antithymocyte globulin treatment at the time of transplantation impairs donor hematopoietic stem cell engraftment
Do you wish to request the book?
Antithymocyte globulin treatment at the time of transplantation impairs donor hematopoietic stem cell engraftment
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Antithymocyte globulin treatment at the time of transplantation impairs donor hematopoietic stem cell engraftment
2017
Overview
Antithymocyte globulin （ATG） is often included in the conditioning regimen to prevent graft vs. host disease in allogeneic hematopoietic stem cell （HSC） transplantation. However, because ATG contains antibodies targeting a wide range of antigens on human cells, its potential off-target effects remain a concern. Here, we explored this question in humanized mice that permit the analysis of human cell depletion in tissues. We showed that ATG binds to almost all lineages of human hematopoietic cells including HSCs, and accordingly it is capable of depleting almost all human hematopoietic cells. Interestingly, the efficacy of ATG was highly variable depending on the tissue of residence, with human cells in bone marrow significantly less susceptible than those in the blood and spleen. Recovery of multilineage human lymphohematopoietic reconstitution in humanized mice that received ATG 3 weeks after HSC transplantation indicates that ATG had a minimal effect on human HSCs that have settled in bone marrow niches. However, efficient human HSC depletion and engraftment failure were seen in mice receiving ATG at the time of transplantation. Our data indicate that the efficacy of ATG is tissue-dependent, and suggest a potential risk of impairing donor hematopoietic engraftment when ATG is used in preparative conditioning regimens.
Publisher
Nature Publishing Group UK,Nature Publishing Group
Subject
/ Antigens
/ Antilymphocyte Serum - pharmacology
/ ATG
/ Biomedical and Life Sciences
/ Female
/ Graft Survival - drug effects
/ Hematopoietic Stem Cell Transplantation
/ Humans
/ Immunosuppressive Agents - pharmacology
/ Mice
/ Rodents
/ Spleen
/ Transplantation Conditioning
/ Vaccine
/ 供体
/ 损害
/ 治疗
/ 球蛋白
/ 移植物抗宿主病
/ 胸腺细胞
/ 造血干细胞移植
